Oxford, UK, 26 April 2022 – Argonaut Therapeutics, a leading developer of novel cancer agents, gave a
company showcase presentation at the BioTrinity 2022 event, an international conference focused on
bio-partnering and investment.
The presentation to an audience of key industry investors and experts highlighted Argonaut Therapeutics
vision to become a leading company in delivering innovative treatments to treat deadly cancers and
provided an overview of the company’s proprietary assets and platforms, with an expanded focus on
novel drug targets discovered in cancer relevant pathways.
BioTrinity is an established, must-attend London conference, that catalyses growth and supports in-
person re-engagement across the life sciences industry. The event is attended by an audience of early
stage and emerging life sciences R&D Companies, investors, big pharma, and other valued partners
throughout the life sciences ecosystem. The conference features a focused, relevant, and stimulating
programme, led by great speakers, who bring their knowledge, expertise, and vision to the fore in
exciting, high-quality sessions.
Professor Nick La Thangue, Founder and Chief Scientific Officer of Argonaut Therapeutics, and
Professor of Cancer Biology in the Department of Oncology at Oxford University, commented:
“Arginine methylation is an extremely important process under aberrant control in many different
cancers and drugs targeting arginine methylation will find clinical utility in diverse indications. We are
delighted to have been invited to present in the oncology session at the BioTrinity 2022 event and
share details on Argonaut’s novel and exciting asset pipeline”.
About Argonaut Therapeutics
Argonaut Therapeutics is a biopharmaceutical company developing new epigenetic therapies for treating
cancer. Its lead programme is focussed on protein arginine methyltransferase 5 (PRMT5) which plays a
key role in attaining the malignant phenotype in many different cancers. Argonaut’s deep scientific
understanding of cancer-relevant pathways affected by arginine methylation enables a precision medicine
approach to treating patients with responsive disease.
Argonaut Therapeutics is a spin-out of Oxford University and maintains a close relationship with the
Division of Medical Sciences.